Description: bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths.
bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath ® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths.
Addressing a critical need to find cancer early and treat cancer specifically, bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. Our first product, CyPath ® Lung , has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test.
Specificity ⃰